Related Experiment Videos
Case report: anti-Cra in pregnancy
A C Dickson1, C Guest, M Jordon
1Patient Serology Laboratory, John Radcliffe Hospital, Headley Way, Oxford OX9 3DU, UK.
Immunohematology
|January 1, 1995
Summary
This study found that the rare anti-Cromer complex antigen a (anti-Cra) antibody did not cause hemolytic disease of the newborn (HDN) in a pregnant patient. The infant showed no signs of HDN, suggesting anti-Cra is not clinically significant in pregnancy.
Area of Science:
- Immunology
- Transfusion Medicine
- Obstetrics
Background:
- The Cromer complex is a group of red blood cell antigens.
- The anti-Cra antibody is rare and its role in hemolytic disease of the newborn (HDN) is poorly understood.
- Few published reports exist regarding anti-Cra and its potential association with HDN.
Purpose of the Study:
- To investigate the clinical significance of the anti-Cra antibody during pregnancy.
- To determine if anti-Cra can cause hemolytic disease of the newborn (HDN).
Main Methods:
- Case study of a pregnant patient with the Cr(a-) phenotype and anti-Cra antibodies.
- In vitro antibody-dependent, cell-mediated cytotoxicity assays were performed.
- Clinical observation of the newborn infant for signs of HDN.
Main Results:
- The patient's red blood cells exhibited the rare Cr(a-) phenotype.
- The patient's serum contained anti-Cra antibodies.
- No functional activity of anti-Cra was detected in vitro.
- No increase in antibody strength was observed during pregnancy.
- The newborn infant showed no clinical signs of HDN and had normal birth weight.
Conclusions:
- Anti-Cra antibodies are not implicated in causing hemolytic disease of the newborn (HDN).
- This case suggests that anti-Cra may not pose a significant clinical risk during pregnancy.
- Further research may be warranted to fully elucidate the clinical implications of anti-Cra.